CADL · Candel Therapeutics, Inc.
$12.35
-1.15 (-8.52%)
At close · Aug 20
Market Cap
$922.05M
Shares
76.52M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.35
Open$13.23
Day$12.33–13.38
52W close$4.42–13.50
Avg vol 30d1.3M
Short int12.7M · 16.5% float · 10.4d
Short vol54%
Last earningsMay 20, 2026
DataJul 2021–Aug 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Feb 23, 2028
Est · unconfirmed
· in 79 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+78%
above
Price vs 50-day avg
+24%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
87%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+25%
trailing
6-month return
+135%
trailing
YTD return
+119%
this year
Relative strength
+124%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
16.54% of float · ▼ -2.4% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
138 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+59%
Y/Y
Free cash flow
$-38.9M
Balance sheet
$118.0M
net cash
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+78%
Bullish
Price vs 50-day avg
+24%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
87%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
16.54% of float · ▼ -2.4% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
138 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $12 · 87%
Range high $14
vs 200-day avg +78%
vs 50-day avg +24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CADL
this stock
Candel Therapeutics, Inc.
|
$922.05M | +118.6% | +0.0% | — | 16.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CADL | +4.7% | +25.3% | +135.2% | +23.4% | +118.6% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +6.6% | +21.9% | +124.1% | +21.3% | +106.8% |
Key facts
CIK
1841387
CUSIP
137404109
13F (30d)
133 filings
132 filers
Visit website
Investor relations